abstract: BACKGROUND: Severe @entity2 and @entity3 are frequently associated with disruptions of coagulation function (such as @entity2 -induced @entity4 TIC) and activation of inflammatory cascades. These pathologies may be exacerbated by current standard of care resuscitation protocols. Observational studies suggest early administration of plasma to severely-injured @entity3 @entity0 may correct TIC, minimise @entity1 , and improve survival. The proposed randomised clinical trial will evaluate the clinical effectiveness of pre-hospital plasma administration compared with standard- of-care crystalloid resuscitation in severely-injured @entity0 with major traumatic @entity3 . METHODS/DESIGN: This is a prospective, randomized, open-label, non-blinded trial to determine the effect of pre-hospital administration of thawed plasma (TP) on mortality, morbidity, transfusion requirements, coagulation, and inflammatory response in severely-injured bleeding @entity2 @entity0 . Two hundred and ten eligible adult @entity2 @entity0 will be randomised to receive either two units of plasma, to be administered in-field, vs standard of care normal saline (NS). Main analyses will compare subjects allocated to TP to those allocated to NS, on an intention-to-treat basis. Primary outcome measure is all-cause 30-day mortality. Secondary outcome measures @entity5 and lipidomic/pro-inflammatory marker responses, volume of resuscitation fluids (crystalloid, colloid) and blood products administered, and major hospital outcomes (e.g. incidence of MSOF, length of ICU stay, length of hospital stay). DISCUSSION: This study is part of a US Department of Defense (DoD)-funded multi-institutional investigation, conducted independently of, but in parallel with, the University of Pittsburgh and University of Denver. Demonstration of significant reductions in mortality and coagulopathic/inflammatory-related morbidities as a result of pre-hospital plasma administration would be of considerable clinical importance for the management of @entity3 in both civilian and military populations. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02303964 on 28 November 2014.

title: Prehospital use of plasma in XXXX (The PUPTH Trial): study protocol for a randomised controlled trial.

answer: @entity3


abstract: AIM: @entity3 ( @entity3 ) require parents to make significant lifestyle changes to accommodate their @entity0 's treatments. We examined the impact of @entity3 -related caregiving on parents' occupational adjustment and labor supply in terms of organizational changes, presenteeism, and absenteeism. METHODS: Nineteen Italian @entity3 referral centers joined the LINFA group. We enrolled 168 adolescents with the disease and their parents (n   =   225) in a cross-sectional survey research. @entity0 and their parents answered a self-administered questionnaire ( @entity0 : SF-12, satisfaction with life, MRC @entity2 scale; parent: caregiver burden scale, short @entity1 -happiness scale, self-rated health, socio-demographic factors). A pediatrician recorded clinical information (pulmonary exacerbations, @entity3 , treatment, BMI percentile, Fev1 %). RESULTS: @entity0 mean age was 16        2.6 and mean BMI percentile was 42.1        29.1; 92 @entity0 (55%) had FEV1 %   >   80. Mean parents' age was 45.9        5.9 years, and 59% were @entity0 ; 75% of @entity0 and 24% of @entity0 reported to be the primary caregiver. Only 12% had a graduate or post-graduate degree and 56.4% were employed. Approximately 34% of parents reported short @entity1 -happiness scale scores suggestive of clinical @entity1 . Higher caregiving strain was associated with increased likelihood of changing job, work shift schedule, or giving up career opportunities in order to fulfill their caregiving role and increased productivity losses due to family leaves and presenteeism. CONCLUSION: Caregiving burden is a relevant and frequent issue among parents of adolescent @entity0 with @entity3 . We showed that the humanistic and vocational impact of caring for young @entity0 with the disease is striking and demands health-care and welfare supportive actions. Pediatr Pulmonol. 2016;51:243-252.    2015 Wiley Periodicals, Inc.

title: Caregiver burden and vocational participation among parents of adolescents with XXXX .

answer: @entity3


abstract: INTRODUCTION: Older @entity12 with a @entity10 substitution have been demonstrated to cause deleterious effects on lipid metabolism profile, as well as frequent @entity8 . The aim of our study is to assess the effects of @entity9 , a novel AED, on lipid metabolism profile, @entity3 values and liver function tests, as well as to compare them with previous effects of @entity5 and @entity6 . METHODS: This report describes a retrospective cohort study of 108 @entity0 who were treated with @entity11 . Of these @entity0 , 52% had switched to @entity11 from prior treatment with @entity5 or @entity6 . Laboratory values concerning lipid metabolism profile, liver function tests and @entity3 were assessed before and after beginning/switching treatment. @entity0 who began treatment or whose treatment for @entity7 was modified during the study period were excluded from the analysis. Co-medications that could impact lipid metabolism profile, @entity3 or hepatic function were kept stable during the study period. RESULTS: The mean total @entity1 of the entire group decreased significantly from prior pathological to normal values after beginning/switching treatment. The percentage of @entity0 with pathological values decreased. @entity0 switching from prior @entity10 also showed significant reductions in mean LDL and @entity4 . @entity0 beginning treatment without prior @entity10 did not develop @entity7 after titration. A tendency for an increased percentage of @entity0 with @entity8 was detected in both groups. CONCLUSIONS: Compared with older @entity10 , @entity9 exhibits a safer profile related to lipid metabolism. No relevant changes were detected in liver function tests. Consequently, a vascular risk factor could be avoided in @entity0 with @entity2 , while @entity8 still needs to be ruled out. Prospective studies are still needed.

title: Assessing long-term effects of XXXX on lipid metabolism profile, @entity3 values and liver function tests.

answer: @entity9


abstract: INTRODUCTION: Older @entity12 with a @entity10 substitution have been demonstrated to cause deleterious effects on lipid metabolism profile, as well as frequent @entity8 . The aim of our study is to assess the effects of @entity9 , a novel AED, on lipid metabolism profile, @entity3 values and liver function tests, as well as to compare them with previous effects of @entity5 and @entity6 . METHODS: This report describes a retrospective cohort study of 108 @entity0 who were treated with @entity11 . Of these @entity0 , 52% had switched to @entity11 from prior treatment with @entity5 or @entity6 . Laboratory values concerning lipid metabolism profile, liver function tests and @entity3 were assessed before and after beginning/switching treatment. @entity0 who began treatment or whose treatment for @entity7 was modified during the study period were excluded from the analysis. Co-medications that could impact lipid metabolism profile, @entity3 or hepatic function were kept stable during the study period. RESULTS: The mean total @entity1 of the entire group decreased significantly from prior pathological to normal values after beginning/switching treatment. The percentage of @entity0 with pathological values decreased. @entity0 switching from prior @entity10 also showed significant reductions in mean LDL and @entity4 . @entity0 beginning treatment without prior @entity10 did not develop @entity7 after titration. A tendency for an increased percentage of @entity0 with @entity8 was detected in both groups. CONCLUSIONS: Compared with older @entity10 , @entity9 exhibits a safer profile related to lipid metabolism. No relevant changes were detected in liver function tests. Consequently, a vascular risk factor could be avoided in @entity0 with @entity2 , while @entity8 still needs to be ruled out. Prospective studies are still needed.

title: Assessing long-term effects of @entity9 on lipid metabolism profile, XXXX values and liver function tests.

answer: @entity3


abstract: OBJECTIVE: To study the association between @entity3 ( @entity3 ) and mode of delivery and to calculate the risks of @entity3 comparing caesarean delivery and operative vaginal delivery to normal vaginal delivery 15-23 years after childbirth. A subgroup analysis comparing forceps and vacuum delivery was planned. DESIGN: Cross-sectional study. SETTING: Postal questionnaire. POPULATION: 1641 (53%) of 3115 @entity0 who delivered their first @entity0 in Trondheim, Norway, between January 1990 and December 1997. METHODS: A questionnaire including questions on symptomatic pelvic organ prolapse, @entity1 and surgery for these conditions. MAIN OUTCOME MEASURES: Prevalence of @entity3 measured by symptomatic pelvic organ prolapse or surgery (sPOP), @entity1 or surgery (UI) and @entity2 or surgery (FI). RESULTS: When caesarean delivery was compared to normal vaginal delivery the adjusted odds ratio (aOR) for sPOP was 0.42 (95% confidence interval, CI, 0.21-0.86) and the aOR for UI was 0.65 (95% CI 0.46-0.92). Operative vaginal delivery was associated with increased risk of sPOP (aOR 1.73, 95% CI 1.21-2.48) and FI (aOR 1.96, 95% CI 1.26-3.06) when compared with normal vaginal delivery. There were no differences in sPOP, UI or FI in a subgroup analysis comparing forceps and vacuum delivery. CONCLUSIONS: Caesarean delivery was associated with decreased risk and operative vaginal delivery with increased risk of @entity3 15-23 years after first delivery, but there were no differences between forceps and vacuum delivery.

title: Pelvic organ prolapse and XXXX 15-23 years after first delivery: a cross-sectional study.

answer: @entity1


abstract: OBJECTIVE: @entity5 , an oral multikinase inhibitor, is the proved therapy method for @entity0 with @entity2 ( @entity2 ). Based on heat delivery, Radiofrequency ablation (RFA) has been found to achieve @entity1 . It is the most widely performed percutaneous therapy for @entity2 . However, Study associated combined @entity5 with RFA therapy for @entity0 with advanced @entity2 has never been reported. The aim of present study is to explore the efficacy and safety of @entity5 combined with RFA therapy for the @entity0 with medium-sized @entity2 . @entity0 AND METHODS: A total of 62 @entity0 diagnosed as @entity2 were involved in this study. All @entity0 were randomly assigned to @entity5 and RFA (n=30) or RFA-alone (n=32) treatment groups. Treatment outcomes, including recurrence rates, @entity4 ( @entity4 ) and adverse reactions induced by @entity5 were observed and recorded to assess the efficacy and safety of the combination method. RESULTS: During the overall follow-up period, the recurrence rate of the combination subgroup was 56.7% (17/30), and that of the RFA-alone subgroup was 87.5% (28/32) (p < 0.01). The median @entity4 was 17.0 months in the combination therapy vs. 6.1 months in the RFA-alone (p < 0.05). Hand-foot skin reactions were reported by 83.3% (25/30) of @entity0 and 46.7% (14/30) reported @entity3 while the most adverse events (AEs) were mild to moderate in the combination subgroup. CONCLUSIONS: @entity5 combined with RFA significantly decreased recurrence rates and prolonged the survival time of medium-sized @entity2 @entity0 . The combination therapy is safer and more effective than the control without unexpected side effects. Furthermore, the earlier application, the better results were.

title: XXXX combined with percutaneous radiofrequency ablation for the treatment of medium-sized @entity2 .

answer: @entity5


abstract: OBJECTIVE: @entity5 , an oral multikinase inhibitor, is the proved therapy method for @entity0 with @entity2 ( @entity2 ). Based on heat delivery, Radiofrequency ablation (RFA) has been found to achieve @entity1 . It is the most widely performed percutaneous therapy for @entity2 . However, Study associated combined @entity5 with RFA therapy for @entity0 with advanced @entity2 has never been reported. The aim of present study is to explore the efficacy and safety of @entity5 combined with RFA therapy for the @entity0 with medium-sized @entity2 . @entity0 AND METHODS: A total of 62 @entity0 diagnosed as @entity2 were involved in this study. All @entity0 were randomly assigned to @entity5 and RFA (n=30) or RFA-alone (n=32) treatment groups. Treatment outcomes, including recurrence rates, @entity4 ( @entity4 ) and adverse reactions induced by @entity5 were observed and recorded to assess the efficacy and safety of the combination method. RESULTS: During the overall follow-up period, the recurrence rate of the combination subgroup was 56.7% (17/30), and that of the RFA-alone subgroup was 87.5% (28/32) (p < 0.01). The median @entity4 was 17.0 months in the combination therapy vs. 6.1 months in the RFA-alone (p < 0.05). Hand-foot skin reactions were reported by 83.3% (25/30) of @entity0 and 46.7% (14/30) reported @entity3 while the most adverse events (AEs) were mild to moderate in the combination subgroup. CONCLUSIONS: @entity5 combined with RFA significantly decreased recurrence rates and prolonged the survival time of medium-sized @entity2 @entity0 . The combination therapy is safer and more effective than the control without unexpected side effects. Furthermore, the earlier application, the better results were.

title: @entity5 combined with percutaneous radiofrequency ablation for the treatment of medium-sized XXXX .

answer: @entity2


abstract: PURPOSE: To investigate oncological outcomes based on bladder cuff excision (BCE) during radical nephroureterectomy (RNU) for upper tract @entity3 (UTUC) and to provide clinical evidence of @entity2 recurrence in @entity0 without BCE. MATERIALS AND METHODS: We retrospectively collected data of 372 consecutive @entity0 who underwent RNU at our institution from May 1989 through October 2010. After excluding some data, we reviewed 336 @entity0 for the analysis. RESULTS: Of the @entity0 who underwent RNU with BCE (n=279, 83.0%) and without BCE (n=57, 17.0%), @entity0 without BCE had poorer @entity2 -specific and overall survival rates. Among 57 @entity0 without BCE, 35 (61.4%) experienced @entity2 recurrence. Recurrence at the remnant ureter resulted in poor oncological outcomes compared to those in @entity0 with @entity4 , but better outcomes were observed compared to recurrence at other sites. No significant predictors for @entity2 recurrence at the remnant ureter were identified. In @entity0 without BCE, pathological T stage [hazard ratio (HR), 5.73] and @entity1 (HR, 3.65) were independent predictors of @entity2 -specific survival, whereas age (HR, 1.04), pathological T stage (HR, 5.11), and positive @entity2 margin (HR, 6.50) were independent predictors of overall survival. CONCLUSION: @entity0 without BCE had poorer overall and @entity2 -specific survival after RNU than those with BCE. Most of these @entity0 experienced @entity2 recurrence at the remnant ureter and other sites. @entity0 with non-organ confined UTUC after RNU without BCE may be considered for adjuvant chemotherapy with careful follow-up.

title: The Characteristics of Recurrent Upper Tract XXXX after Radical Nephroureterectomy without Bladder Cuff Excision.

answer: @entity3


abstract: BACKGROUND: Prenatal @entity1 exposure (PAE) is associated with alterations in numerous physiological systems, including the stress and immune systems. We have previously shown that PAE increases the course and severity of @entity2 in an @entity4 ( @entity4 ) model. While the molecular mechanisms underlying these effects are not fully known, changes in neural gene expression are emerging as important factors in the etiology of PAE effects. As the prefrontal cortex (PFC) and hippocampus (HPC) play key roles in neuroimmune function, PAE-induced alterations to their transcriptome may underlie abnormal steady-state functions and responses to immune challenge. This study examined brains from adult PAE and control females from our recent @entity4 study to determine whether PAE causes long-term alterations in gene expression and whether these mediate the altered severity and course of @entity2 in PAE females. METHODS: Adult females from PAE, pair-fed (PF), and ad libitum-fed control (C) groups were injected with either saline or complete Freund's adjuvant. Animals were terminated at the peak of @entity0 or during resolution (Days 16 and 39 postinjection, respectively); cohorts of saline-injected PAE, PF, and C females were terminated in parallel. Gene expression was analyzed in the PFC and HPC using whole-genome mRNA expression microarrays. RESULTS: Significant changes in gene expression in both the PFC and HPC were found in PAE compared to controls in response to @entity3 exposure alone (saline-injected females), including genes involved in neurodevelopment, apoptosis, and energy metabolism. Moreover, in response to @entity0 (adjuvant-injected females), PAE animals showed unique expression patterns, while failing to exhibit the activation of genes and regulators involved in the immune response observed in control and pair-fed animals. CONCLUSIONS: These results support the hypothesis that PAE affects neuroimmune function at the level of gene expression, demonstrating long-term effects of PAE on the central nervous system response under steady-state conditions and following an inflammatory insult.

title: Prenatal XXXX exposure alters steady-state and activated gene expression in the adult rat brain.

answer: @entity1


abstract: BACKGROUND: Extracranial @entity7 is an important cause of @entity2 , especially in young @entity0 . In some observational studies it has been associated with a high risk of recurrent @entity2 . Both antiplatelet drugs and anticoagulant drugs are used to reduce risk of @entity2 but whether one treatment strategy is more effective than the other is unknown. We compared their efficacy in the Cervical @entity7 in @entity2 Study (CADISS), with the additional aim of establishing the true risk of recurrent @entity2 . METHODS: We did this randomised trial at hospitals with specialised @entity2 or neurology services (39 in the UK and seven in Australia). We included @entity0 with extracranial carotid and vertebral dissection with onset of symptoms within the past 7 days. @entity0 were randomly assigned (1:1) by an automated telephone randomisation service to receive antiplatelet drugs or anticoagulant drugs (specific treatment decided by the local clinician) for 3 months. @entity0 and clinicians were not masked to allocation, but investigators assessing endpoints were. The primary endpoint was @entity2 or @entity3 in the intention-to-treat population. The trial was registered with EUDract (2006-002827-18) and ISRN (CTN44555237). FINDINGS: We enrolled 250 @entity0 (118 carotid, 132 vertebral). Mean time to randomisation was 3  65 days (SD 1  91). The major presenting symptoms were @entity2 or transient ischaemic attack (n=224) and local symptoms ( @entity1 , @entity6 , or @entity8 ; n=26). 126 @entity0 were assigned to antiplatelet treatment versus 124 to anticoagulant treatment. Overall, four (2%) of 250 @entity0 had @entity2 recurrence (all ipsilateral). @entity2 or @entity3 occurred in three (2%) of 126 @entity0 versus one (1%) of 124 (odds ratio [OR] 0  335, 95% CI 0  006-4  233; p=0  63). There were no deaths, but one major @entity5 ( @entity4 ) in the anticoagulant group. Central review of imaging failed to confirm dissection in 52 @entity0 . Preplanned per-protocol analysis excluding these @entity0 showed @entity2 or @entity3 in three (3%) of 101 @entity0 in the antiplatelet group versus one (1%) of 96 @entity0 in the anticoagulant group (OR 0  346, 95% CI 0  006-4  390; p=0  66). INTERPRETATION: We found no difference in efficacy of antiplatelet and anticoagulant drugs at preventing @entity2 and @entity3 in @entity0 with symptomatic @entity7 but @entity2 was rare in both groups, and much rarer than reported in some observational studies. Diagnosis of dissection was not confirmed after review in many cases, suggesting that radiographic criteria are not always correctly applied in routine clinical practice. FUNDING: @entity2 Association.

title: Antiplatelet treatment compared with anticoagulation treatment for cervical XXXX (CADISS): a randomised trial.

answer: @entity7


abstract: OBJECTIVES: Long-term magnetic resonance angiography (MRA) follow-up studies regarding cryptogenic nonperimesencephalic @entity2 (nSAH) are scarce. This single-centre study identified all @entity0 with angiographically verified cryptogenic nSAH from 1998 to 2007: The two main objectives were to prospectively assess the incidence of de novo @entity1 with 3.0-MRI years after cryptogenic nSAH in @entity0 without evidence for further @entity3 , and retrospectively assess @entity0 demographics and outcome. METHODS: From prospectively maintained report databases all @entity0 with angiographically verified cryptogenic nSAH were identified. 21 of 29 @entity0 received high-resolution 3T-MRI including time-of-flight and contrast-enhanced angiography, 10.2    2.8 years after cryptogenic nSAH. MRA follow-up imaging was compared with initial digital subtraction angiography (DSA) and CT/MRA. Post- @entity3 images were related to current MRI with reference to persistent lesions resulting from delayed @entity5 (DCI) and post-hemorrhagic @entity6 . @entity0 -based objectives were retrospectively abstracted from clinical databases. RESULTS: 29 @entity0 were identified with cryptogenic nSAH, 17 (59%) were male. Mean age at time of @entity3 was 52.9    14.4 years (range 4 - 74 years). 21 @entity0 were available for long-term follow-up. In these, there were 213.5 @entity0 years of MRI-follow-up. No de novo @entity1 was detected. Mean modified Rankin Scale (mRS) during discharge was 1.28. Post- @entity3 radiographic @entity4 was found in three @entity0 (10.3%); DCI-related lesions occurred in one @entity0 (3.4%). Five @entity0 (17.2%) needed temporary external ventricular drainage; long-term CSF shunt dependency was necessary only in one @entity0 (3.4%). Initial DSA retrospectively showed a 2 x 2 mm @entity1 of the right distal ICA in one @entity0 , which remained stable. Post- @entity3 @entity6 was detected 8.1 years after the initial @entity3 in one @entity0 (4.8%). CONCLUSION: @entity0 with cryptogenic nSAH have favourable outcomes and do not exhibit higher risks for de novo @entity1 . Therefore the need for long-term follow up after cryptogenic nSAH is questionable.

title: MR Angiography Follow-Up 10 Years after Cryptogenic Nonperimesencephalic XXXX .

answer: @entity2


abstract: UNASSIGNED: @entity1 is perceived following binding to endoplasmic reticulum-localized receptors, which in @entity0 , include @entity4 , @entity7 , @entity5 , @entity8 , and @entity9 . These receptors fall into two subfamilies based on conservation of features within their @entity2 kinase domain. Subfamily 1 contains @entity4 and @entity7 whereas subfamily 2 contains @entity5 , @entity8 , and @entity9 . Because @entity1 receptors are found only in plants, this raises questions of when each receptor evolved. Here it is shown that subfamily 1 receptors encoded by a multigene family are present in all charophytes examined, these being most homologous to @entity4 based on their evolutionary relationship as well as containing @entity2 kinase and receiver domains. In charophytes and @entity3 , one or more gene family members contain the intron characteristic of subfamily 2 genes, indicating the first step in subfamily 2 receptor evolution. @entity7 homologs appear in basal angiosperm species after @entity6 and, in some early and basal angiosperm species and monocots in general, it is the only subfamily 1 receptor present. Distinct @entity5 and @entity8 homologs appear only in core eudicots and @entity9 homologs appear only in the Brassicaceae, suggesting it is the most recent receptor to evolve. These findings show that a subfamily 1 receptor had evolved and a subfamily 2 receptor had begun to evolve in plants prior to the colonization of land and only these two existed up to the appearance of the first basal angiosperm. The appearance of @entity9 in the Brassicaceae suggests ongoing evolution of the @entity1 receptor family.

title: Appearance and elaboration of the XXXX receptor family during land plant evolution.

answer: @entity1


abstract: UNASSIGNED: The goal of this study is to validate a new, continuous, noninvasive @entity1 volume (SV) method, known as transbrachial electrical bioimpedance velocimetry ( @entity4 ). @entity4 SV was compared to SV obtained by cardiac magnetic resonance imaging (cMRI) in normal @entity0 devoid of clinically apparent @entity2 . Thirty-two (32) volunteers were enrolled in the study. Each subject was evaluated by echocardiography to assure that no aortic or @entity3 was present. Subsequently, each subject underwent electrical interrogation of the brachial artery by means of a high frequency, low amplitude alternating current. A first @entity4 SV estimate was obtained. Immediately after the initial @entity4 study, subjects underwent cMRI, using steady-state precession imaging to obtain a volumetric estimate of SV. Following cMRI, the @entity4 SV study was repeated. Comparing the cMRI-derived SV to that of @entity4 , the two @entity4 estimates were averaged and compared to the cMRI standard. CO was computed as the product of SV and heart rate. Statistical methods consisted of Bland-Altman and linear regression analysis. @entity4 SV and CO estimates were obtained in 30 of the 32 subjects enrolled. Bland-Altman analysis of pre- and post-cMRI @entity4 SV showed a mean bias of 2.87 % (2.05  mL), precision of 13.59  % (11.99  mL) and 95  % limits of agreement (LOA) of +29.51  % (25.55  mL) and -23.77  % (-21.45  mL). Regression analysis for pre- and post-cMRI @entity4 SV values yielded y  =  0.76x  +  25.1 and r(2)  =  0.71 (r  =  0.84). Bland-Altman analysis comparing cMRI SV with averaged @entity4 SV showed a mean bias of -1.56  % (-1.53  mL), precision of 13.47  % (12.84  mL), 95  % LOA of +24.85  % (+23.64  mL) and -27.97  % (-26.7  mL) and percent error  =  26.2  %. For correlation analysis, the regression equation was y  =  0.82x  +  19.1 and correlation coefficient r(2)  =  0.61 (r  =  0.78). Bland-Altman analysis of averaged pre- and post-cMRI @entity4 CO versus cMRI CO yielded a mean bias of 5.01  % (0.32  L  min(-1)), precision of 12.85  % (0.77  L  min(-1)), 95  % LOA of +30.20  % (+0.1.83  L  min(-1)) and -20.7  % (-1.19  L  min(-1)) and percent error  =  24.8  %. Regression analysis yielded y  =  0.92x  +  0.78, correlation coefficient r(2)  =  0.74 (r  =  0.86). @entity4 is a novel, noninvasive method, which provides satisfactory estimates of SV and CO in normal @entity0 .

title: Validation of XXXX volume and cardiac output by electrical interrogation of the brachial artery in normals: assessment of strengths, limitations, and sources of error.

answer: @entity1


abstract: BACKGROUND: @entity2 @entity8 is associated with major morbidity and mortality. However, its prevalence has mainly been selectively studied in populations at risk for @entity3 . Taking into account improvements in recording techniques and new criteria used to define respiratory events, we aimed to assess the prevalence of @entity2 @entity8 and associated clinical features in a large population-based sample. METHODS: Between Sept 1, 2009, and June 30, 2013, we did a population-based study (HypnoLaus) in Lausanne, Switzerland. We invited a cohort of 3043 consecutive @entity0 of the CoLaus/PsyCoLaus study to take part. Polysomnography data from 2121 @entity0 were included in the final analysis. 1024 (48%) @entity0 were @entity0 , with a median age of 57 years (IQR 49-68, range 40-85) and mean body-mass index (BMI) of 25  6 kg/m(2) (SD 4  1). @entity0 underwent complete polysomnographic recordings at home and had extensive phenotyping for @entity1 , @entity5 , @entity6 , and @entity7 . The primary outcome was prevalence of @entity2 @entity8 , assessed by the apnoea-hypopnoea index. FINDINGS: The median apnoea-hypopnoea index was 6  9 events per h (IQR 2  7-14  1) in @entity0 and 14  9 per h (7  2-27  1) in @entity0 . The prevalence of moderate-to-severe @entity2 @entity8 (>= 15 events per h) was 23  4% (95% CI 20  9-26  0) in @entity0 and 49  7% (46  6-52  8) in @entity0 . After multivariable adjustment, the upper quartile for the apnoea-hypopnoea index (>20  6 events per h) was associated independently with the presence of @entity5 (odds ratio 1  60, 95% CI 1  14-2  26; p=0  0292 for trend across severity quartiles), @entity1 (2  00, 1  05-3  99; p=0  0467), @entity6 (2  80, 1  86-4  29; p<0  0001), and @entity7 (1  92, 1  01-3  64; p=0  0292). INTERPRETATION: The high prevalence of @entity2 @entity8 recorded in our population-based sample might be attributable to the increased sensitivity of current recording techniques and scoring criteria. These results suggest that @entity2 @entity8 is highly prevalent, with important public health outcomes, and that the @entity4 should be revised. FUNDING: Faculty of Biology and Medicine of Lausanne, Lausanne University Hospital, Swiss National Science Foundation, Leenaards Foundation, GlaxoSmithKline, Ligue Pulmonaire Vaudoise.

title: Prevalence of XXXX @entity8 in the general population: the HypnoLaus study.

answer: @entity2


abstract: BACKGROUND: @entity2 @entity8 is associated with major morbidity and mortality. However, its prevalence has mainly been selectively studied in populations at risk for @entity3 . Taking into account improvements in recording techniques and new criteria used to define respiratory events, we aimed to assess the prevalence of @entity2 @entity8 and associated clinical features in a large population-based sample. METHODS: Between Sept 1, 2009, and June 30, 2013, we did a population-based study (HypnoLaus) in Lausanne, Switzerland. We invited a cohort of 3043 consecutive @entity0 of the CoLaus/PsyCoLaus study to take part. Polysomnography data from 2121 @entity0 were included in the final analysis. 1024 (48%) @entity0 were @entity0 , with a median age of 57 years (IQR 49-68, range 40-85) and mean body-mass index (BMI) of 25  6 kg/m(2) (SD 4  1). @entity0 underwent complete polysomnographic recordings at home and had extensive phenotyping for @entity1 , @entity5 , @entity6 , and @entity7 . The primary outcome was prevalence of @entity2 @entity8 , assessed by the apnoea-hypopnoea index. FINDINGS: The median apnoea-hypopnoea index was 6  9 events per h (IQR 2  7-14  1) in @entity0 and 14  9 per h (7  2-27  1) in @entity0 . The prevalence of moderate-to-severe @entity2 @entity8 (>= 15 events per h) was 23  4% (95% CI 20  9-26  0) in @entity0 and 49  7% (46  6-52  8) in @entity0 . After multivariable adjustment, the upper quartile for the apnoea-hypopnoea index (>20  6 events per h) was associated independently with the presence of @entity5 (odds ratio 1  60, 95% CI 1  14-2  26; p=0  0292 for trend across severity quartiles), @entity1 (2  00, 1  05-3  99; p=0  0467), @entity6 (2  80, 1  86-4  29; p<0  0001), and @entity7 (1  92, 1  01-3  64; p=0  0292). INTERPRETATION: The high prevalence of @entity2 @entity8 recorded in our population-based sample might be attributable to the increased sensitivity of current recording techniques and scoring criteria. These results suggest that @entity2 @entity8 is highly prevalent, with important public health outcomes, and that the @entity4 should be revised. FUNDING: Faculty of Biology and Medicine of Lausanne, Lausanne University Hospital, Swiss National Science Foundation, Leenaards Foundation, GlaxoSmithKline, Ligue Pulmonaire Vaudoise.

title: Prevalence of @entity2 XXXX in the general population: the HypnoLaus study.

answer: @entity8


abstract: UNASSIGNED: Recent years have seen a significant increase in the reports of atypical antipsychotic diversion, misuse and even dependency syndrome. These reports have arisen amidst a marked increase in prescribing of these agents. Much of this increase in prescribing is because of a preferential use of these medications over typical antipsychotic agents to treat @entity1 and @entity2 due to perceptions of fewer extrapyramidal side effects. However, there has also been a significant increase in the off-label prescribing of these medicines to treat less well evidence-based conditions. Misuse and abuse are perhaps surprising given the putative central role of @entity3 in addiction and that these agents are @entity3 antagonists. However, there may be other factors such as other pharmacological effects and increasing availability driving this misuse. It is also apparent that certain @entity0 groups appear to be more at risk. Here, we explore the evidence behind the misuse of atypical antipsychotics with a focus of @entity4 . We consider the factors that may be driving this misuse, and then, we also detail some of the adverse effects that may ensue. We end by suggesting interventions at a prescriber and systems level that may be implemented to reduce the risk of atypical antipsychotic misuse.

title: Misuse and Associated Harms of XXXX and Other Atypical Antipsychotics.

answer: @entity4


abstract: UNASSIGNED: @entity0 with huge @entity3 >10  cm in diameter represent a special subgroup for treatment. To date, there are few data and little consensus on treatment strategies for huge @entity3 . In this study, we summarized the effects and safety of transarterial chemoembolization for huge @entity3 . A retrospective study was performed based on a large cohort of @entity0 (n  =  511) with huge @entity3 who underwent serial transarterial chemoembolization between January 2008 to December 2011 and were followed up until March 2013. We found median survival time was 6.5  months. On multivariate analysis, @entity0 -Pugh class (A versus B) (p  <  0.0001), @entity4 ( <=400    g/L) (p  =  0.002), Barcelona Clinic @entity2 stage (B versus C) (p  =  0.013), and other treatments after transarterial chemoembolization such as surgical resection (p  =  0.008), radiation (p  =  0.018), and local radiofrequency ablation (p  =  0.002) were factors significantly associated with better  overall @entity0 survival after chemoembolization. Twenty-nine percent of these @entity0 showed a @entity1 response after serial transarterial chemoembolization. Severe complications were few (4.9  %), including @entity6 (n  =  3), @entity1 rupture (n  =  3), @entity5 (n  =  4), @entity9 (n  =  3), acute @entity10 (n  =  4), femoral @entity11 (n  =  1), acute @entity7 (n  =  1), and @entity8 (n  =  6). In conclusion, transarterial chemoembolization is a safe and effective treatment for selected @entity0 with huge @entity3 and is recommended as a component of combination therapy. In addition, @entity0 with good liver function and low @entity4 levels may acquire greater survival benefits from transarterial chemoembolization.

title: Transarterial chemoembolization for huge XXXX with diameter over ten centimeters: a large cohort study.

answer: @entity3


abstract: The effect of a new psychostimulant, mesocarb was determined on the in vitro uptake of biogenic @entity6 into synaptosomes prepared from whole @entity0 brain and various cerebral regions. @entity7 was also examined as reference compound. On the other hand, the effects of mesocarb and @entity7 were compared in vivo on the uptake of @entity4 (CA) using an indirect method based on the inhibiton of cerebral CA depletion caused by intraventricularly injected @entity5 ( @entity5 ). Mesocarb was found to block the synaptosomal uptake of @entity2 (DA) in the striatum and whole brain more effectively than @entity7 , but inhibited the @entity3 (NA) uptake into hypothalamus much less than @entity7 . The effect of mesocarb on @entity1 ( @entity1 ) uptake was not significant, similarly as that of @entity7 . On the other hand, mesocarb inhibited the decrease of brain DA levels but had no protecting effect against NA depletion caused by @entity5 , in vivo. @entity7 dose-dependently inhibited NA depletion caused by @entity5 but did not inhibit DA depletion. These findings indicate that mesocarb is a specific inhibitor of in vitro synaptosomal CA uptake, with an activity for striatal and whole brain DA uptake blockade much higher than that of @entity7 . The results also show that mesocarb is a selective inhibitor of DA uptake in vivo, in contrast to @entity7 , which preferentially blocks the uptake of NA in the brain. This difference may presumably be responsible for the different psychostimulatory action of the two compounds.

title: Inhibition of XXXX uptake by a new psychostimulant mesocarb (Sydnocarb).

answer: @entity2


abstract: INTRODUCTION: The long-term morbidity associated with treating @entity4 can be significant. @entity5 ( @entity5 ) has established oncologic efficacy in treating @entity6 with minimal long-term @entity2 . We describe our experience with @entity5 as a front-line treatment of lymph node-positive @entity8 . MATERIALS AND METHODS: We reviewed our institutional review board-approved @entity1 database to find the @entity0 with pure @entity8 and isolated @entity5 who had undergone primary @entity5 . The clinical and pathologic variables were obtained. The follow-up data were used to determine recurrence and @entity3 . RESULTS: Four @entity0 with a mean age of 37 years were identified. All @entity0 had normal @entity1 markers and @entity7 measuring 1.1, 1.5, 1.8, and 5.5 cm before @entity5 . Of the 4 @entity0 , 3 had had @entity8 diagnosed at orchiectomy and 1 (with a 5.5-cm @entity7 and a burned out primary testicular mass) had had @entity8 diagnosed at @entity5 after 2 nondiagnostic retroperitoneal biopsies. All @entity0 had undergone nerve-sparing, template, extraperitoneal @entity5 and were discharged home after 3 days. An average of 3 positive lymph nodes were found. Of the 4 @entity0 , 3 had pathologic stage IIA and 1 stage IIB disease, with no @entity0 undergoing adjuvant therapy. At a mean follow-up period of 25 months, no @entity0 had experienced disease recurrence, and none had died. All @entity0 maintained antegrade ejaculation, and no long-term complications had developed. CONCLUSION: Our small series has demonstrated encouraging oncologic efficacy for @entity5 as a primary treatment of retroperitoneal lymph node-positive @entity8 . A multi-institutional phase II trial of @entity5 for stage @entity8 is being developed.

title: Retroperitoneal Lymph Node Dissection as First-Line Treatment of Node-Positive XXXX .

answer: @entity8


abstract: BACKGROUND: According to epidemiological and experimental studies, inhalation of nanoparticles is commonly believed as a main trigger for several @entity1 and @entity1 . Concerning the transport and deposition of such nano-scale particles in the different structures of the @entity0 lungs, some essential questions are still in need of a clarification. Therefore, main objective of the study was the simulation of nanoparticle deposition in the alveolar region of the @entity0 respiratory tract (HRT). METHODS: Respective factors describing the aerodynamic behavior of spherical and non-spherical particles in the inhaled air stream (i.e., Cunningham slip correction factors, dynamic shape factors, equivalent-volume diameters, aerodynamic diameters) were computed. Alveolar deposition of diverse nanomaterials according to several known mechanisms, among which Brownian diffusion and sedimentation play a superior role, was approximated by the use of empirical and analytical formulae. Deposition calculations were conducted with a currently developed program, termed NANODEP, which allows the variation of numerous input parameters with regard to particle geometry, lung morphometry, and aerosol inhalation. RESULTS: Generally, alveolar deposition of nanoparticles concerned for this study varies between 0.1% and 12.4% during sitting @entity2 and between 2.0% and 20.1% during heavy-exercise @entity2 . @entity3 particles (e.g., nanotubes) exhibit a significant increase in deposition, when their aspect ratio is enhanced. In contrast, deposition of oblate particles (e.g., nanoplatelets) is remarkably declined with any reduction of the aspect ratio. CONCLUSIONS: The study clearly demonstrates that alveolar deposition of nanoparticles represents a topic certainly being of superior interest for physicists and respiratory physicians in future.

title: A computer model for the simulation of nanoparticle deposition in the alveolar structures of the XXXX lungs.

answer: @entity0


abstract: @entity7 is a @entity4 endemic to the southwestern United States that typically causes a self-limited @entity3 . Extrapulmonary dissemination is extremely rare and typically localized to the skin, bone, and meninges. The gastrointestinal system has generally been thought to be spared from this disease. This report describes a @entity0 who was initially diagnosed with @entity3 with @entity1 . Ten months after completion of treatment, he presented with nonspecific @entity5 and diffuse musculoskeletal and constitutional symptoms. Radiographic imaging revealed near resolution of previously noted thoracic findings but new peritoneal thickening and enhancement suggestive of @entity2 . Laparoscopic biopsies confirmed @entity8 by culture and histology without evidence of other abnormalities. This case is unique for several reasons. It is one of a relatively small number of cases that describes a diagnosis of peritoneal @entity7 and the first case identified in which a healthy @entity0 developed extensive @entity6 in spite of near-complete resolution of pulmonary and skin manifestations after appropriate treatment. This case underscores the complexity of this disease and motivates more investigation into pathophysiology and treatment considerations of @entity7 in the gastrointestinal system. We will review the risk factors associated with dissemination, the interpretation of serologies, the characteristics of @entity0 with peritoneal involvement, and finally, the current treatment guidelines.

title: Peritoneal XXXX : a Rare Case Report and Review of the Literature.

answer: @entity7


abstract: UNASSIGNED: Background: @entity1 ( @entity1 ) are a group of @entity2 in childhood and adolescence. Beside genetic predisposition also environmental influences may contribute to the @entity3 pathogenesis. Family members of @entity0 and adolescents with @entity3 often ask for specific diets to alleviate @entity3 -associated symptoms. The aim of this review is to provide evidence-based data on nutritional interventions for @entity0 and adolescents with @entity3 , thus enabling practitioners to competently assess these diets. Methods: Applying defined inclusion and exclusion criteria, a systematic literature research in PubMed, Cinahl and The Cochrane Library was conducted. Studies published earlier than 1999 were excluded. Study quality was assessed by using the CONSORT, STROBE or PRISMA checklist, respectively. Results: 12 randomised controlled studies and 2 non-controlled studies could be included in the evaluation (n=971). There is no proven efficacy of the widely used gluten-free casein-free diets (GFCF), and no respective predictive marker has been proven significant. Conclusion: Based on available data, no evidence based recommendations regarding nutritional interventions for @entity0 and adolescents with @entity1 can be made. Future studies need to clarify whether particular @entity0 may yet benefit from certain diets.

title: [Nutritional Therapy for XXXX and Adolescents with Autism Spectrum Disorders: What is the Evidence?]

answer: @entity0


abstract: @entity3 ( @entity3 ) were considered an extremely rare disease. However, in recent years, the number of @entity0 with @entity5 has increased rapidly. According to an epidemiological survey conducted in Japan, the number of treated @entity0 with @entity3 in 2010 was approximately 1.2-times that in 2005, and the number of new incidences of non-functional @entity3 in 2010 was approximately 1.7-times that in 2005. Among functional @entity3 , @entity8 was most prevalent, followed by @entity6 . To diagnose @entity3 , correct histological diagnosis is most important. According to the World Health Organization 2010 classification criteria, @entity2 ( @entity2 ) are categorized into well-differentiated @entity2 and poorly differentiated @entity4 ( @entity4 ). @entity4 accounted for 7.6% of all @entity2 , and functional and non-functional @entity3 accounted for 2.1% and 10.1%, respectively. @entity0 with distant @entity1 accounted for 19.9%, and those with @entity7 accounted for 4.3%. When treating @entity3 , it is necessary to correctly evaluate the functionality and progression of @entity2 , the presence or absence of @entity1 , and the degrees of differentiation and malignant potential of @entity2 . A new registration system from the Japan @entity2 Society will start to be used in 2015, which will help further dissemination of Japanese epidemiological information to the world.

title: The up-to-date review of epidemiological pancreatic XXXX in Japan.

answer: @entity2


abstract: UNASSIGNED: @entity1 (SA) is a key hormone that mediates gene transcriptional reprogramming in the context of the defense response to stress. GRXC9, coding for a CC-type @entity3 from @entity0 , is an SA-responsive gene induced early and transiently by an @entity2 -independent pathway. Here, we address the mechanism involved in this SA-dependent pathway, using GRXC9 as a model gene. We first established that GRXC9 expression is induced by UVB exposure through this pathway, validating its activation in a physiological stress condition. GRXC9 promoter analyses indicate that SA controls gene transcription through two activating sequence-1 (as-1)-like elements located in its proximal region. @entity4 and @entity5 , but not @entity6 , are constitutively bound to this promoter region. Accordingly, the transient recruitment of RNA polymerase II to the GRXC9 promoter, as well as the transient accumulation of gene transcripts detected in SA-treated WT plants, was abolished in a knockout mutant for the TGA class II factors. We conclude that constitutive binding of @entity4 is essential for controlling GRXC9 expression, while binding of @entity5 in a lesser extent contributes to this regulation. Finally, overexpression of GRXC9 indicates that the GRXC9 protein negatively controls its own gene expression, forming part of the complex bound to the as-1-containing promoter region. These findings are integrated in a model that explains how SA controls transcription of GRXC9 in the context of the defense response to stress.

title: Transcriptional Control of @entity3 GRXC9 Expression by a XXXX -Dependent and @entity2 -Independent Pathway in @entity0 .

answer: @entity1


abstract: UNASSIGNED: @entity1 (SA) is a key hormone that mediates gene transcriptional reprogramming in the context of the defense response to stress. GRXC9, coding for a CC-type @entity3 from @entity0 , is an SA-responsive gene induced early and transiently by an @entity2 -independent pathway. Here, we address the mechanism involved in this SA-dependent pathway, using GRXC9 as a model gene. We first established that GRXC9 expression is induced by UVB exposure through this pathway, validating its activation in a physiological stress condition. GRXC9 promoter analyses indicate that SA controls gene transcription through two activating sequence-1 (as-1)-like elements located in its proximal region. @entity4 and @entity5 , but not @entity6 , are constitutively bound to this promoter region. Accordingly, the transient recruitment of RNA polymerase II to the GRXC9 promoter, as well as the transient accumulation of gene transcripts detected in SA-treated WT plants, was abolished in a knockout mutant for the TGA class II factors. We conclude that constitutive binding of @entity4 is essential for controlling GRXC9 expression, while binding of @entity5 in a lesser extent contributes to this regulation. Finally, overexpression of GRXC9 indicates that the GRXC9 protein negatively controls its own gene expression, forming part of the complex bound to the as-1-containing promoter region. These findings are integrated in a model that explains how SA controls transcription of GRXC9 in the context of the defense response to stress.

title: Transcriptional Control of XXXX GRXC9 Expression by a @entity1 -Dependent and @entity2 -Independent Pathway in @entity0 .

answer: @entity3


abstract: UNASSIGNED: @entity1 (SA) is a key hormone that mediates gene transcriptional reprogramming in the context of the defense response to stress. GRXC9, coding for a CC-type @entity3 from @entity0 , is an SA-responsive gene induced early and transiently by an @entity2 -independent pathway. Here, we address the mechanism involved in this SA-dependent pathway, using GRXC9 as a model gene. We first established that GRXC9 expression is induced by UVB exposure through this pathway, validating its activation in a physiological stress condition. GRXC9 promoter analyses indicate that SA controls gene transcription through two activating sequence-1 (as-1)-like elements located in its proximal region. @entity4 and @entity5 , but not @entity6 , are constitutively bound to this promoter region. Accordingly, the transient recruitment of RNA polymerase II to the GRXC9 promoter, as well as the transient accumulation of gene transcripts detected in SA-treated WT plants, was abolished in a knockout mutant for the TGA class II factors. We conclude that constitutive binding of @entity4 is essential for controlling GRXC9 expression, while binding of @entity5 in a lesser extent contributes to this regulation. Finally, overexpression of GRXC9 indicates that the GRXC9 protein negatively controls its own gene expression, forming part of the complex bound to the as-1-containing promoter region. These findings are integrated in a model that explains how SA controls transcription of GRXC9 in the context of the defense response to stress.

title: Transcriptional Control of @entity3 GRXC9 Expression by a @entity1 -Dependent and XXXX -Independent Pathway in @entity0 .

answer: @entity2


abstract: UNASSIGNED: @entity1 (SA) is a key hormone that mediates gene transcriptional reprogramming in the context of the defense response to stress. GRXC9, coding for a CC-type @entity3 from @entity0 , is an SA-responsive gene induced early and transiently by an @entity2 -independent pathway. Here, we address the mechanism involved in this SA-dependent pathway, using GRXC9 as a model gene. We first established that GRXC9 expression is induced by UVB exposure through this pathway, validating its activation in a physiological stress condition. GRXC9 promoter analyses indicate that SA controls gene transcription through two activating sequence-1 (as-1)-like elements located in its proximal region. @entity4 and @entity5 , but not @entity6 , are constitutively bound to this promoter region. Accordingly, the transient recruitment of RNA polymerase II to the GRXC9 promoter, as well as the transient accumulation of gene transcripts detected in SA-treated WT plants, was abolished in a knockout mutant for the TGA class II factors. We conclude that constitutive binding of @entity4 is essential for controlling GRXC9 expression, while binding of @entity5 in a lesser extent contributes to this regulation. Finally, overexpression of GRXC9 indicates that the GRXC9 protein negatively controls its own gene expression, forming part of the complex bound to the as-1-containing promoter region. These findings are integrated in a model that explains how SA controls transcription of GRXC9 in the context of the defense response to stress.

title: Transcriptional Control of @entity3 GRXC9 Expression by a @entity1 -Dependent and @entity2 -Independent Pathway in XXXX .

answer: @entity0


abstract: Background and Objective. @entity5 is associated with decreased survival and increased complications in @entity3 @entity0 . We hypothesized that sarcopenic soft-tissue @entity4 (STS) @entity0 would have decreased survival, increased incidence of wound complications, and increased length of postresection hospital stay (LOS). Methods. A retrospective, single-center review of 137 @entity0 treated surgically for STS was conducted. @entity5 was assessed by measuring the cross-sectional area of bilateral psoas muscles (total psoas muscle area, TPA) at the level of the third lumbar vertebrae on a pretreatment axial computed tomography scan. TPA was then adjusted for height (cm(2)/m(2)). The association between height-adjusted TPA and survival was assessed using Cox proportional hazard model. A logistical model was used to assess the association between height-adjusted TPA and wound complications. A linear model was used to assess the association between height-adjusted TPA and LOS. Results. Height-adjusted TPA was not an independent predictor of overall survival (p = 0.746). @entity0 age (p = 0.02) and @entity1 size (p = 0.009) and grade (p = 0.001) were independent predictors of overall survival. Height-adjusted TPA was not a predictor of increased hospital LOS (p = 0.66), greater incidence of @entity2 (p = 0.56), or other wound complications (p = 0.14). Conclusions. @entity5 does not appear to impact overall survival, LOS, or wound complications in @entity0 with STS.

title: @entity5 Does Not Affect Survival or Outcomes in Soft-Tissue XXXX .

answer: @entity4


abstract: Background and Objective. @entity5 is associated with decreased survival and increased complications in @entity3 @entity0 . We hypothesized that sarcopenic soft-tissue @entity4 (STS) @entity0 would have decreased survival, increased incidence of wound complications, and increased length of postresection hospital stay (LOS). Methods. A retrospective, single-center review of 137 @entity0 treated surgically for STS was conducted. @entity5 was assessed by measuring the cross-sectional area of bilateral psoas muscles (total psoas muscle area, TPA) at the level of the third lumbar vertebrae on a pretreatment axial computed tomography scan. TPA was then adjusted for height (cm(2)/m(2)). The association between height-adjusted TPA and survival was assessed using Cox proportional hazard model. A logistical model was used to assess the association between height-adjusted TPA and wound complications. A linear model was used to assess the association between height-adjusted TPA and LOS. Results. Height-adjusted TPA was not an independent predictor of overall survival (p = 0.746). @entity0 age (p = 0.02) and @entity1 size (p = 0.009) and grade (p = 0.001) were independent predictors of overall survival. Height-adjusted TPA was not a predictor of increased hospital LOS (p = 0.66), greater incidence of @entity2 (p = 0.56), or other wound complications (p = 0.14). Conclusions. @entity5 does not appear to impact overall survival, LOS, or wound complications in @entity0 with STS.

title: XXXX Does Not Affect Survival or Outcomes in Soft-Tissue @entity4 .

answer: @entity5


abstract: UNASSIGNED: The aim of this study was to determine whether autophagy and @entity4 contribute to premature senescence in auditory cells. Incubating HEI-OC1 auditory cells with 5 mM @entity0 for 1 h induced senescence, as demonstrated by senescence-associated b-galactosidase (SA-b-gal) staining. @entity0 treatment significantly delayed population-doubling time, leaving cell viability unchanged. Furthermore, the proportion of SA-b-gal-positive cells significantly increased. Autophagy-related protein expression increased, with @entity3 and LC3-II peaking 6 h and @entity1 peaking 24 h after @entity0 treatment. The expression of these proteins decreased 48 h after treatment. Transmission electron microscopy revealed lipofuscin and aggregates within autolysosomes, which accumulated markedly in the cytoplasm of HEI-OC1 cells 48 h after treatment. Akt and P70S6 phosphorylation markedly decreased after @entity0 treatment, but @entity2 phosphorylation significantly increased 48 h after treatment. After RNAi-mediated knockdown (KD) of @entity3 and @entity4 , @entity0 -treated cells displayed dense SA-b-gal staining. Also, premature senescence was significantly induced. These suggest that a negative feedback loop may exist between autophagy and @entity4 signaling pathways in HEI-OC1 cells. In our model, oxidative stress-induced premature senescence occurred due to impaired autophagy function through @entity2 phosphorylation. Our results also indicate that @entity4 may regulate premature senescence in auditory cells in an autophagy-dependent and independent manner.

title: Autophagy through XXXX and @entity4 regulates oxidative stress-induced premature senescence in auditory cells.

answer: @entity2


abstract: UNASSIGNED: The aim of this study was to determine whether autophagy and @entity4 contribute to premature senescence in auditory cells. Incubating HEI-OC1 auditory cells with 5 mM @entity0 for 1 h induced senescence, as demonstrated by senescence-associated b-galactosidase (SA-b-gal) staining. @entity0 treatment significantly delayed population-doubling time, leaving cell viability unchanged. Furthermore, the proportion of SA-b-gal-positive cells significantly increased. Autophagy-related protein expression increased, with @entity3 and LC3-II peaking 6 h and @entity1 peaking 24 h after @entity0 treatment. The expression of these proteins decreased 48 h after treatment. Transmission electron microscopy revealed lipofuscin and aggregates within autolysosomes, which accumulated markedly in the cytoplasm of HEI-OC1 cells 48 h after treatment. Akt and P70S6 phosphorylation markedly decreased after @entity0 treatment, but @entity2 phosphorylation significantly increased 48 h after treatment. After RNAi-mediated knockdown (KD) of @entity3 and @entity4 , @entity0 -treated cells displayed dense SA-b-gal staining. Also, premature senescence was significantly induced. These suggest that a negative feedback loop may exist between autophagy and @entity4 signaling pathways in HEI-OC1 cells. In our model, oxidative stress-induced premature senescence occurred due to impaired autophagy function through @entity2 phosphorylation. Our results also indicate that @entity4 may regulate premature senescence in auditory cells in an autophagy-dependent and independent manner.

title: Autophagy through @entity2 and XXXX regulates oxidative stress-induced premature senescence in auditory cells.

answer: @entity4


abstract: AIM: To discuss current dosage for stereotactic body radiation therapy (SBRT) in @entity4 ( @entity4 ) @entity0 and suggest alternative treatment strategies according to @entity5 as defined by the Couinaud classification. BACKGROUND: SBRT is a safe and effective alternative treatment for @entity4 @entity0 who are unable to undergo liver ablation/resection. However, the SBRT fractionation schemes and treatment planning strategies are not well established. MATERIALS AND METHODS: In this article, the latest developments and key findings from research studies exploring the efficacy of SBRT fractionation schemes for treatment of @entity4 are reviewed. @entity0 ' characteristics, fractionation schemes, treatment outcomes and @entity3 were compiled. Special attention was focused on SBRT fractionation approaches that take into consideration @entity5 according to the Couinaud classification and functional hepatic reserve based on @entity0 -Pugh (CP) liver @entity2 classification. RESULTS: The most common SBRT fractionation schemes for @entity4 were 3  *  10-20  Gy, 4-6  *  8-10  Gy, and 10  *  5-5.5  Gy. Based on previous SBRT studies, and in consideration of @entity1 size and CP classification, we proposed 3  *  15-25  Gy for @entity0 with @entity1 size <3  cm and adequate liver reserve (CP-A score 5), 5  *  10-12  Gy for @entity0 with @entity1 sizes between 3 and 5  cm or inadequate liver reserve (CP-A score 6), and 10  *  5-5.5  Gy for @entity0 with @entity1 size >5  cm or @entity6 score. CONCLUSIONS: Treatment schemes in SBRT for @entity4 vary according to @entity5 . Further prospective studies may be necessary to identify the optimal dose of SBRT for @entity4 .

title: Stereotactic body radiation therapy in @entity4 : Optimal treatment strategies based on XXXX .

answer: @entity5


abstract: AIM: To discuss current dosage for stereotactic body radiation therapy (SBRT) in @entity4 ( @entity4 ) @entity0 and suggest alternative treatment strategies according to @entity5 as defined by the Couinaud classification. BACKGROUND: SBRT is a safe and effective alternative treatment for @entity4 @entity0 who are unable to undergo liver ablation/resection. However, the SBRT fractionation schemes and treatment planning strategies are not well established. MATERIALS AND METHODS: In this article, the latest developments and key findings from research studies exploring the efficacy of SBRT fractionation schemes for treatment of @entity4 are reviewed. @entity0 ' characteristics, fractionation schemes, treatment outcomes and @entity3 were compiled. Special attention was focused on SBRT fractionation approaches that take into consideration @entity5 according to the Couinaud classification and functional hepatic reserve based on @entity0 -Pugh (CP) liver @entity2 classification. RESULTS: The most common SBRT fractionation schemes for @entity4 were 3  *  10-20  Gy, 4-6  *  8-10  Gy, and 10  *  5-5.5  Gy. Based on previous SBRT studies, and in consideration of @entity1 size and CP classification, we proposed 3  *  15-25  Gy for @entity0 with @entity1 size <3  cm and adequate liver reserve (CP-A score 5), 5  *  10-12  Gy for @entity0 with @entity1 sizes between 3 and 5  cm or inadequate liver reserve (CP-A score 6), and 10  *  5-5.5  Gy for @entity0 with @entity1 size >5  cm or @entity6 score. CONCLUSIONS: Treatment schemes in SBRT for @entity4 vary according to @entity5 . Further prospective studies may be necessary to identify the optimal dose of SBRT for @entity4 .

title: Stereotactic body radiation therapy in XXXX : Optimal treatment strategies based on @entity5 .

answer: @entity4


abstract: Until now, treatment of primary @entity5 of the warm type (wAIHA) is primarily based on immunosuppression. However, many @entity0 do not respond adequately to treatment, and treated @entity0 may develop severe side effects due to uncontrolled, mixed and/or long-lasting immunosuppression. Unfortunately, the newly used therapeutic monoclonal antibodies are unspecific and remain frequently ineffective. Thus, development of a specific therapy for AIHA is necessary. The ideal therapy would be the identification and elimination of the causative origin of autoimmunization and/or the correction or reprogramming of the dysregulated immune components. Blood transfusion is the most rapidly effective measure for @entity0 who develop or may develop @entity1 . Although some effort has been made to guide physicians on how to adequately treat @entity0 with AIHA, a number of individual aspects should be considered prior to treatment. Based on my serological and clinical experience and the analysis of evidence-based studies, we remain far from any optimized therapeutic measures for all AIHA @entity0 . Today, the old standard therapy using controlled @entity2 administration, with or without @entity3 or @entity4 , is, when complemented with erythropoiesis-stimulating agents, still the most effective therapy in wAIHA. Rituximab or other monoclonal antibodies may be used instead of splenectomy in therapy-refractory @entity0 .

title: Treatment Options for Primary XXXX : A Short Comprehensive Review.

answer: @entity5


abstract: BACKGROUND: @entity2 is the most common @entity1 in the world. The cutaneous form is rare in low endemic countries. The occurrence of several @entity3 cases in our dermatology department during 2011-2012 led us to investigate whether there was a resurgence of @entity3 in France. The aim was to analyse changes in @entity3 and the related clinical, microbiological and therapeutic data. @entity0 AND METHODS: We conducted a retrospective study in our hospital between 2005 and 2012 by querying the PMSI database (code: A 18.4). Epidemiological, clinical, paraclinical and therapeutic data were collected. @entity4 was regarded as a variety of @entity3 . RESULTS: Thirteen @entity0 presented @entity3 between 2005 and 2012. The most frequent clinical forms were @entity4 of Bazin (n=6) and @entity3 (n=3). Microbiological evidence was provided in only 4 cases. DISCUSSION: Diagnosis is difficult due to the varied clinical forms and to the relatively high frequency of paucibacillary forms. Further, the set of additional examinations is non-specific. In some cases, it is only therapeutic tests that allow diagnosis to be made. The place of new diagnostic tools must be clarified and a universally acceptable definition of @entity4 devised.

title: [Cutaneous XXXX and @entity4 : A retrospective study of 13 cases in France.]

answer: @entity2


abstract: BACKGROUND: @entity2 is the most common @entity1 in the world. The cutaneous form is rare in low endemic countries. The occurrence of several @entity3 cases in our dermatology department during 2011-2012 led us to investigate whether there was a resurgence of @entity3 in France. The aim was to analyse changes in @entity3 and the related clinical, microbiological and therapeutic data. @entity0 AND METHODS: We conducted a retrospective study in our hospital between 2005 and 2012 by querying the PMSI database (code: A 18.4). Epidemiological, clinical, paraclinical and therapeutic data were collected. @entity4 was regarded as a variety of @entity3 . RESULTS: Thirteen @entity0 presented @entity3 between 2005 and 2012. The most frequent clinical forms were @entity4 of Bazin (n=6) and @entity3 (n=3). Microbiological evidence was provided in only 4 cases. DISCUSSION: Diagnosis is difficult due to the varied clinical forms and to the relatively high frequency of paucibacillary forms. Further, the set of additional examinations is non-specific. In some cases, it is only therapeutic tests that allow diagnosis to be made. The place of new diagnostic tools must be clarified and a universally acceptable definition of @entity4 devised.

title: [Cutaneous @entity2 and XXXX : A retrospective study of 13 cases in France.]

answer: @entity4


abstract: BACKGROUND: @entity5 (CD105) is a cytokine that modulates angiogenesis by regulating different cellular functions, including endothelial proliferation, differentiation, migration and formation of microvessels. CD105 is expressed strongly in the @entity2 vasculature, and intratumoral microvessel density (IMVD), as determined by the use of antibodies to CD105, it has been found to be an important prognostic indicator for outcome in various malignances. This study aims to determine if the clinical outcome of @entity0 with @entity3 is correlated with IMVD, as determined by CD105 staining and other prognostic factors. PROCEDURE: Tumor tissue specimens from 38 @entity0 with peripheral @entity2 who underwent surgical resection or biopsy of their @entity2 without any preoperative therapy were retrospectively reviewed. IMVD was identified immunohistochemically using monoclonal antibodies against CD105. Prognostic factors, such as the @entity4 oncogene, disease stage, histopathology and age, were correlated with outcome. RESULTS: Among 38 examined specimens, the median IMVD value was 23.2 (15.1-28.4). The IMVD identified by CD105 was significantly higher in @entity0 with unfavorable histology, @entity1 , @entity4 amplification and COG high risk group. ROC analysis was used to find significant IMVD level regarding EFS. The cut-off >18 was selected according to the greatest sensitivity (100%) and specificity (68.42%). The multivariate Cox proportional hazards analysis demonstrated that @entity4 amplification and IMVD were significant prognostic factors in predicting EFS (hazard ratio for @entity4 amplification: 3.61; 95% CI: 1.20-10.90; P   =   0.023 and for IMVD: 1.05; 95% CI: 1.00-1.09; P   =   0.037). CONCLUSION: IMVD determined by CD105 appeared to be an independent prognostic factor for @entity3 . Pediatr @entity2    2015 Wiley Periodicals, Inc.

title: XXXX (CD 105) as a potential prognostic factor in @entity3 .

answer: @entity5


abstract: BACKGROUND: @entity5 (CD105) is a cytokine that modulates angiogenesis by regulating different cellular functions, including endothelial proliferation, differentiation, migration and formation of microvessels. CD105 is expressed strongly in the @entity2 vasculature, and intratumoral microvessel density (IMVD), as determined by the use of antibodies to CD105, it has been found to be an important prognostic indicator for outcome in various malignances. This study aims to determine if the clinical outcome of @entity0 with @entity3 is correlated with IMVD, as determined by CD105 staining and other prognostic factors. PROCEDURE: Tumor tissue specimens from 38 @entity0 with peripheral @entity2 who underwent surgical resection or biopsy of their @entity2 without any preoperative therapy were retrospectively reviewed. IMVD was identified immunohistochemically using monoclonal antibodies against CD105. Prognostic factors, such as the @entity4 oncogene, disease stage, histopathology and age, were correlated with outcome. RESULTS: Among 38 examined specimens, the median IMVD value was 23.2 (15.1-28.4). The IMVD identified by CD105 was significantly higher in @entity0 with unfavorable histology, @entity1 , @entity4 amplification and COG high risk group. ROC analysis was used to find significant IMVD level regarding EFS. The cut-off >18 was selected according to the greatest sensitivity (100%) and specificity (68.42%). The multivariate Cox proportional hazards analysis demonstrated that @entity4 amplification and IMVD were significant prognostic factors in predicting EFS (hazard ratio for @entity4 amplification: 3.61; 95% CI: 1.20-10.90; P   =   0.023 and for IMVD: 1.05; 95% CI: 1.00-1.09; P   =   0.037). CONCLUSION: IMVD determined by CD105 appeared to be an independent prognostic factor for @entity3 . Pediatr @entity2    2015 Wiley Periodicals, Inc.

title: @entity5 (CD 105) as a potential prognostic factor in XXXX .

answer: @entity3


abstract: UNASSIGNED: Objectives. We examined whether a @entity2 ( @entity2 ) clinic could reach @entity0 who had not received a Papanicolau (Pap) test in the past 3 years. We also explored staff attitudes and implementation of @entity1 screening. Methods. @entity0 (n   =   123) aged 30 to 50 years were offered @entity1 screening in an Indiana @entity2 clinic. We measured effectiveness by the @entity0 ' self-reported last Pap test. We explored adoption of screening through focus groups with 34 staff members by documenting their attitudes about @entity1 screening and screening strategy adaptation. We also documented recruitment and screening implementation. Results. Almost half (47.9%) of @entity0 reported a last Pap test 3 or more years previously; 30% had reported a last Pap more than 5 years ago, and 11.4% had a high-risk test outcome that required referral to colposcopy. Staff supported screening because of mission alignment and perceived @entity0 benefit. Screening adaptations included eligibility, results provision, and follow-up. Conclusions. @entity1 screening was possible and potentially beneficial in @entity2 clinics. Future effectiveness implementation studies should expand to include all female @entity0 , and should examine the degree to which adaptation of selected adoption frameworks is feasible. (Am J Public Health. Published online ahead of print February 17, 2015: e1-e7. doi:10.2105/AJPH.2014.302272).

title: @entity1 Screening in a XXXX Clinic: Screening Adoption Experiences From a Midwestern Clinic.

answer: @entity2


abstract: UNASSIGNED: Objectives. We examined whether a @entity2 ( @entity2 ) clinic could reach @entity0 who had not received a Papanicolau (Pap) test in the past 3 years. We also explored staff attitudes and implementation of @entity1 screening. Methods. @entity0 (n   =   123) aged 30 to 50 years were offered @entity1 screening in an Indiana @entity2 clinic. We measured effectiveness by the @entity0 ' self-reported last Pap test. We explored adoption of screening through focus groups with 34 staff members by documenting their attitudes about @entity1 screening and screening strategy adaptation. We also documented recruitment and screening implementation. Results. Almost half (47.9%) of @entity0 reported a last Pap test 3 or more years previously; 30% had reported a last Pap more than 5 years ago, and 11.4% had a high-risk test outcome that required referral to colposcopy. Staff supported screening because of mission alignment and perceived @entity0 benefit. Screening adaptations included eligibility, results provision, and follow-up. Conclusions. @entity1 screening was possible and potentially beneficial in @entity2 clinics. Future effectiveness implementation studies should expand to include all female @entity0 , and should examine the degree to which adaptation of selected adoption frameworks is feasible. (Am J Public Health. Published online ahead of print February 17, 2015: e1-e7. doi:10.2105/AJPH.2014.302272).

title: XXXX Screening in a @entity2 Clinic: Screening Adoption Experiences From a Midwestern Clinic.

answer: @entity1


abstract: OBJECTIVE: To determine if @entity5 ( @entity6 ) enhances the impact in excitatory presynaptic terminals of a rate-limiting mechanism in vesicle trafficking termed supply rate @entity2 that emerges to limit synaptic transmission during heavy, epileptiform use. METHODS: The effect of @entity6 was measured with electrophysiologic assays of monosynaptic connections in ex vivo hippocampal slices from wild-type and synapsin knockout @entity0 , and in primary cell culture neurons from wild-type and @entity7 ( @entity7 ) knockout @entity0 . RESULTS: @entity6 enhanced the impact of supply rate @entity2 at Schaffer collateral synapses by shortening the time course for induction. The @entity6 effect was selective for supply rate @entity2 because other presynaptic vesicle trafficking mechanisms were not affected. The half maximal effective concentration (EC50 ) was ~50   m. The maximal effect was ~15  % and occurred at 100   m, which is a clinically relevant concentration. An experimental protocol is established for distinguishing atypical @entity3 ( @entity3 ) that affect supply rate @entity2 , such as @entity6 , from typical @entity3 , such as @entity4 , that affect upstream mechanisms. The @entity6 effect was abolished at synapses from knockout @entity0 lacking @entity7 and from synapses lacking synapsin 1 and 2. SIGNIFICANCE: The findings are consistent with the new hypothesis that @entity6 acts to treat @entity1 by accelerating the induction of supply rate @entity2 at excitatory synapses during incipient @entity1 activity. The absence of the effect in the knockouts confirms that presynaptic function is the target. More specifically, the absence in @entity7 knockouts is consistent with previous binding studies suggesting that @entity7 is the target for @entity6 . The absence in synapsin knockouts indicates that the phenotypic target intersects with the biochemical pathway that is altered in synapsin knockouts. The results from synapsin knockouts additionally suggest that development of functional analogs with increased potency might be possible because induction of supply rate @entity2 is faster in synapsin knockouts compared to wild-type synapses treated with @entity6 .

title: XXXX accelerates the onset of supply rate @entity2 in synaptic vesicle trafficking.

answer: @entity5


abstract: OBJECTIVE: To determine if @entity5 ( @entity6 ) enhances the impact in excitatory presynaptic terminals of a rate-limiting mechanism in vesicle trafficking termed supply rate @entity2 that emerges to limit synaptic transmission during heavy, epileptiform use. METHODS: The effect of @entity6 was measured with electrophysiologic assays of monosynaptic connections in ex vivo hippocampal slices from wild-type and synapsin knockout @entity0 , and in primary cell culture neurons from wild-type and @entity7 ( @entity7 ) knockout @entity0 . RESULTS: @entity6 enhanced the impact of supply rate @entity2 at Schaffer collateral synapses by shortening the time course for induction. The @entity6 effect was selective for supply rate @entity2 because other presynaptic vesicle trafficking mechanisms were not affected. The half maximal effective concentration (EC50 ) was ~50   m. The maximal effect was ~15  % and occurred at 100   m, which is a clinically relevant concentration. An experimental protocol is established for distinguishing atypical @entity3 ( @entity3 ) that affect supply rate @entity2 , such as @entity6 , from typical @entity3 , such as @entity4 , that affect upstream mechanisms. The @entity6 effect was abolished at synapses from knockout @entity0 lacking @entity7 and from synapses lacking synapsin 1 and 2. SIGNIFICANCE: The findings are consistent with the new hypothesis that @entity6 acts to treat @entity1 by accelerating the induction of supply rate @entity2 at excitatory synapses during incipient @entity1 activity. The absence of the effect in the knockouts confirms that presynaptic function is the target. More specifically, the absence in @entity7 knockouts is consistent with previous binding studies suggesting that @entity7 is the target for @entity6 . The absence in synapsin knockouts indicates that the phenotypic target intersects with the biochemical pathway that is altered in synapsin knockouts. The results from synapsin knockouts additionally suggest that development of functional analogs with increased potency might be possible because induction of supply rate @entity2 is faster in synapsin knockouts compared to wild-type synapses treated with @entity6 .

title: @entity5 accelerates the onset of supply rate XXXX in synaptic vesicle trafficking.

answer: @entity2


abstract: UNASSIGNED: @entity2 markedly reduces quality of life and causes a significant psychological burden for @entity0 who are severely affected by this @entity3 . Pharmacologic and surgical treatments for @entity2 exist, but for @entity0 who have failed medical therapy and are not surgical candidates, stereotactic radiosurgery is the only available treatment option. Of available stereotactic radiosurgical techniques for intractable @entity2 , the authors chose to evaluate the safety and efficacy of gamma knife stereotactic radiosurgical thalamotomy. In order to qualitatively synthesize available data a systematic review was conducted by searching MEDLINE (OvidSP 1946-January Week 1 2014) and Embase (OvidSP 1974-2014 January). The search strategy was not limited by study design or language of publication. All searches were conducted on January 7, 2014. Treatment efficacy, adverse outcomes, and @entity0 deaths were reviewed and tabulated. Complications appeared months to years post procedure and most commonly consisted of mild @entity4 and @entity5 . Rarely, more severe complications were reported, including @entity6 and @entity1 . Though no data from randomized controlled trials are available, our analysis of the literature indicates that unilateral gamma knife thalamotomy using doses from 130 to 150Gy appears safe and well tolerated.

title: Gamma knife stereotactic radiosurgical thalamotomy for intractable XXXX : A systematic review of the literature.

answer: @entity2


abstract: UNASSIGNED: Many @entity1 ( @entity1 ) survivors experience reduced quality of life due to radiotherapy (RT)-related @entity2 . The aim of this prospective randomized trial was to evaluate the impact of prophylactic swallowing exercises on swallowing-related outcomes in @entity1 @entity0 treated with curative RT. @entity0 treated with primary RT for @entity1 were candidates for this randomized protocol. @entity0 in the exercise group were instructed to perform swallowing exercises at home. @entity0 in the control group were given standard care. @entity0 were evaluated with modified barium swallow and several other secondary outcome measures at four and nine different time points, respectively. Data were analyzed according to intention-to-treat analyses. A total of 44 consecutive @entity0 were included; 22 in each group. In general, there was no difference between the two groups regarding any of the @entity2 outcomes during and after treatment. Adherence to exercises was poor and dropouts due to especially fatigue were very frequent in both groups. Systematic swallowing exercises had no impact on swallowing outcomes within the first year after RT. Despite repeated supervised sessions, adherence to exercises was a major issue and dropouts were frequent in both the intervention and control group.

title: Prophylactic Swallowing Exercises in XXXX Radiotherapy.

answer: @entity1


abstract: OBJECTIVES: To identify the association of fibronectin (FN) extra domain A ( @entity4 ) with the progression of salivary @entity3 (SACC). Accordingly, the exclusion of @entity4 exon through the CRISPR/Cas9 system was investigated as the rescue for such pro-oncogenic splicing. MATERIALS AND METHODS: SACC-83 cells were transiently transfected with plasmids containing recombinant @entity4 , and the cellular growth and motility were then accessed in vitro. Epithelial-mesenchymal transition (EMT) was investigated with immunohistochemistry, Western blot, and real-time PCR analysis. SACC tissues from 81 @entity0 were used to access the associations between @entity4 +FN and clinical-pathological parameters. CRISPR/Cas9 plasmids containing sgRNA were designed and co-transfected into SACC-83 cells; the effects of @entity4 knockout on cellular growth and motility were then accessed. RESULTS: The recombinant @entity4 exhibited little effect on the proliferation of SACC cells, but significantly promoted the migration and invasion of the cells (P  <  0.05), accompanied with upregulated EMT (P  <  0.05); consistently, the expression of @entity4 +FN was positively associated with the @entity1 , nerve invasion and recurrence of SACC (P  <  0.05). Furthermore, the @entity4 knockout from the FN gene in most SACC cells resulted in a decrease in cell motility and invasion, as well as prolonged population doubling time, compared with untreated SACC-83 cells (P  <  0.05). CONCLUSION: The @entity4 domain significantly promoted the motility of SACC cells, and positively associated with the @entity2 progression in @entity0 with SACC. Thus, it is a potential risk factor and also a therapeutic target for SACC. The CRISPR/Cas9 system may control a pro-oncogenic splicing process through the exclusion of @entity4 exon from the FN gene, leading to inhibition of motility, invasion and proliferation of @entity2 cells.

title: The CRISPR/Cas system inhibited the pro-oncogenic effects of alternatively spliced fibronectin extra domain A via editing the genome in salivary XXXX cells.

answer: @entity3


abstract: In recent years, there has been an increasing interest in the pathophysiology of repetitive concussive @entity4 (rcTBI) in large part due to the association with dramatic cases of progressive @entity1 in professional athletes, military personnel, and others. However, our understanding of the pathophysiology of rcTBI is less advanced than for more severe @entity7 . Most prominently, the mechanisms underlying traumatic @entity2 , microglial activation, @entity6 , and progressive tau pathology are not yet known. In addition, the role of injury to dendritic spine cytoskeletal structures, vascular reactivity impairments, and microthrombi are intriguing and subjects of ongoing inquiry. Methods for quantitative analysis of @entity2 , @entity3 , and synaptic loss need to be refined for the field to move forward in a rigorous fashion. We and others are attempting to develop translational approaches to assess these specific pathophysiological events in both animals and @entity0 to facilitate clinically relevant pharmacodynamic assessments of candidate therapeutics. In this article, we review and discuss several of the recent experimental results from our lab and others. We include new initial data describing the difficulty in modeling progressive tau pathology in experimental rcTBI, and results demonstrating that @entity8 can alleviate social interaction deficits and @entity5 -like behaviors following experimental rcTBI plus foot shock stress. Furthermore, we propose a discrete set of open, experimentally tractable questions that may serve as a framework for future investigations. In addition, we also raise several important questions that are less experimentally tractable at this time, in hopes that they may stimulate future methodological developments to address them. This article is part of a Special Issue entitled " @entity4 ".

title: The pathophysiology of repetitive concussive XXXX in experimental models; new developments and open questions.

answer: @entity4


abstract: UNASSIGNED: The deterioration of semen quality occurs very early after @entity1 ( @entity1 ). Thus, routine cryopreservation of semen early after injury has been recommended. However, there is currently a lack of data concerning the effects of long-term cryopreservation on the quality of spermatozoa from @entity1 @entity0 . We have therefore investigated the quality of spermatozoa from @entity1 @entity0 before and after long-term cryopreservation. The semen cryobank of a @entity1 rehabilitation center was screened for samples with a storage duration of more than 3  years, to carry out a cross-sectional study regarding the sperm quality of semen samples from @entity1 @entity0 . Semen quality analysis was carried out according to the WHO-Guidelines. The quality of 28 semen samples from 16 @entity1 @entity0 was investigated prior to and a median 11  years (95% CI 7-13  years) after cryopreservation. Prior to cryopreservation, ejaculate volume (median  =  1.7  mL, 95% CI 1-3  mL) and sperm concentration (median  =  106  *  10(6) /mL, 95% CI 82-132  *  10(6) /mL) were within normal limits, but total sperm motility (median  =  19%, 95% CI 13-22%) and viability (median  =  27%, 95% CI 19-45%) were reduced. Cryopreservation resulted in a significant (p  <  0.0001) decrease in total sperm motility (median  =  2.5%, 95% CI 0-4%) and viability (median  =  7%, 95% CI 6-13%). There were no significant (p  =  0.75) differences between the semen parameters of samples collected early (up to 3  weeks) after @entity1 and those collected later. Complete @entity1 had a significantly (p  <  0.0001) negative effect on the sperm viability of the fresh semen samples, and @entity2 had a significantly (p  <  0.035) negative effect on both pre-cryopreservation sperm viability and post-cryopreservation motility. The assisted ejaculation technique had no significant (p  >  0.053) effect on semen quality. Long-term cryopreservation of semen from @entity1 @entity0 results in essentially immotile sperm with minimal viability. Thus, routine long-term cryobanking of semen harvested early after @entity1 cannot be recommended.

title: Cross-sectional study of the sperm quality in semen samples from spinal cord injured XXXX after long-term cryopreservation.

answer: @entity0


abstract: OBJECTIVES: In idiopathic normal pressure @entity5 (NPH) ventriculoperitoneal (VP) shunt insertion is the method of choice to improve cardinal symptoms such as gait disturbance, urge @entity3 and/or @entity2 . With reduced compliance, the brain of the elderly is prone for overdrainage complications. This was especially true with the use of differential pressure valve implantation. The present study compares clinical outcome and complication rates after VP shunt insertion with differential pressure valves in the early years and gravitational valves since 2005. METHODS: The authors reviewed @entity0 treated at our institution for NPH since 1995. Differential pressure valves were solely used in the initial years, while the treatment regimen changed to gravitational valves in 2005. Clinical improvement/surgical success rates as well as complications were compared between the two groups. RESULTS: Eighty-nine @entity0 were enrolled for the present study. Mean age at the time of surgery was 73.5        6.3  years. Male @entity0 predominated with 73, compared with 16 female @entity0 . Median follow-up time was 28        26  months. Date of last follow-up was 1st October 2013. Forty-nine @entity0 received a gravitational valve, while 40 were treated with differential pressure valves. In the gravitational group a significant improvement was observed after shunt insertion for @entity4 , @entity1 and urge @entity3 (p   <   0.0001, resp. p   =   0.004), while a significant change in the differential pressure group was only seen for @entity4 (p   =   0.03) but not for cognition or urinary incontinency (p   >   0.05). The risk of @entity6 as a sign of shunt overdrainage requiring surgical intervention was significantly higher in the differential pressure group (5 versus 0 in the gravitational group). CONCLUSIONS: @entity0 with NPH treated with gravitational valves in the present cohort showed a more profound improvement in their initial symptoms, including @entity4 , @entity1 and urinary incontinency without the risk of overdrainage complications requiring surgical intervention when compared with @entity0 who received differential pressure valves in previous years.

title: Optimized surgical treatment for normal pressure XXXX : comparison between gravitational and differential pressure valves.

answer: @entity5


abstract: UNASSIGNED: The purpose of this investigation was to evaluate the potential dosimetric benefits of a two-phase adaptive intensity-modulated radiotherapy (IMRT) protocol for @entity0 with locally advanced @entity1 ( @entity1 ). A total of 17 @entity0 with locally advanced @entity1 treated with IMRT had a second computed tomography (CT) scan after 17 fractions in order to apply and continue the treatment with an adapted plan after 20 fractions. To simulate the situation without adaptation, a hybrid plan was generated by applying the optimization parameters of the original treatment plan to the anatomy of the second CT scan. The dose-volume histograms (DVHs) and dose statistics of the hybrid plan and the adapted plan were compared. The mean volume of the ipsilateral and contralateral parotid gland decreased by 6.1 cm(3) (30.5%) and 5.4 cm(3) (24.3%), respectively. Compared with the hybrid plan, the adapted plan provided a higher dose to the target volumes with better homogeneity, and a lower dose to the organs at risk (OARs). The Dmin of all planning target volumes (PTVs) increased. The Dmax of the spinal cord and brainstem were lower in 94% of the @entity0 (1.6-5.9 Gy, P < 0.001 and 2.1-9.9 Gy, P < 0.001, respectively). The Dmean of the contralateral parotid decreased in 70% of the @entity0 (range, 0.2-4.4 Gy). We could not find a relationship between dose variability and @entity2 . Our two-phase adaptive IMRT protocol improves dosimetric results in terms of target volumes and OARs in @entity0 with locally advanced @entity1 .

title: A dosimetric comparison of two-phase adaptive intensity-modulated radiotherapy for locally advanced XXXX .

answer: @entity1


abstract: UNASSIGNED: Purpose. To determine the impact of intraoperative magnetic resonance imaging (iMRI) in @entity2 surgeries on the extent of surgical resection and @entity3 outcome along with its feasibility and limitations. Methods. @entity0 with pharmacoresistant @entity2 (PRE), who underwent surgeries in operating theater equipped with high-field 1.5-Tesla MRI, were evaluated for extent of resection, operative time, scanning time, pathologies, resultant extra resection, and @entity3 outcomes. Results. Thirty-nine @entity0 with mean age of 18 (range: 3-65) years with PRE underwent surgical intervention. Mean duration of @entity2 was 10.2 years. Surgical interventions included @entity1 resection (31%), resection of focal @entity5 (28%), mesial temporal lobe surgeries (18%), and disconnection surgeries (23%). iMRI alone, apart from navigation and electrophysiology, improved resection rates in 13% (5 out of 39) of these @entity0 . In lesional group, iMRI modified operative strategy resulting in increased resections in 21% (5/23) @entity0 . Complete resection was observed in 87% of @entity0 . iMRI scanning time constituted 25% (mean: 72    21 min) of time spent under anesthesia by the @entity0 . Major and minor complications were observed in 2.5% and 7.5% of @entity0 , respectively. The mean follow-up was 14 months. Favorable postoperative @entity3 control (Engel Classes I and II) was achieved in 85% and complete @entity3 freedom was achieved in 77% of @entity0 (Engel Class IA) at 1-year follow-up. Conclusions. iMRI increases the extent of resection mainly in lesional @entity2 surgeries translating into good @entity3 outcomes but not found to be much beneficial in prototype mesial temporal @entity4 surgeries and disconnection surgeries.

title: Impact of intraoperative MRI on outcomes in XXXX surgery: preliminary experience of two years.

answer: @entity2


abstract: OBJECTIVE: The aim of this study is to present and discuss the results of a European multicentre prospective study about pediatric maxillofacial @entity1 epidemiology during a year. STUDY DESIGN: The following data were recorded: gender, age, etiology, site of @entity2 , date of injury. Of the 3396 @entity0 with maxillofacial @entity2 admitted within the study period, 114 (3.3%) were @entity0 aged 15 years and younger, with a male/female ratio of 2.6:1. Mean age was 10.9 years. Most @entity0 (63%) were aged 11-15 years. RESULTS: The most frequent cause of injury was fall (36 @entity0 ). Sport injuries and assaults were almost limited to the oldest group, whereas falls were more uniformly distributed in the 3 groups. The most frequently observed @entity2 involved the mandible with 47 @entity2 . In particular, 18 condylar @entity2 were recorded, followed by 12 body @entity2 . CONCLUSIONS: Falls can be acknowledged as the most important cause of facial @entity1 during the first years of life. The high incidence of sport accidents after 10 years may be a reason to increase the use of mouthguards and other protective equipment. Finally, the mandible (and in particular the condyle) was confirmed as the most frequent @entity2 site.

title: European Maxillofacial XXXX (EURMAT) in @entity0 : A multicenter and prospective study.

answer: @entity1


abstract: OBJECTIVE: The aim of this study is to present and discuss the results of a European multicentre prospective study about pediatric maxillofacial @entity1 epidemiology during a year. STUDY DESIGN: The following data were recorded: gender, age, etiology, site of @entity2 , date of injury. Of the 3396 @entity0 with maxillofacial @entity2 admitted within the study period, 114 (3.3%) were @entity0 aged 15 years and younger, with a male/female ratio of 2.6:1. Mean age was 10.9 years. Most @entity0 (63%) were aged 11-15 years. RESULTS: The most frequent cause of injury was fall (36 @entity0 ). Sport injuries and assaults were almost limited to the oldest group, whereas falls were more uniformly distributed in the 3 groups. The most frequently observed @entity2 involved the mandible with 47 @entity2 . In particular, 18 condylar @entity2 were recorded, followed by 12 body @entity2 . CONCLUSIONS: Falls can be acknowledged as the most important cause of facial @entity1 during the first years of life. The high incidence of sport accidents after 10 years may be a reason to increase the use of mouthguards and other protective equipment. Finally, the mandible (and in particular the condyle) was confirmed as the most frequent @entity2 site.

title: European Maxillofacial @entity1 (EURMAT) in XXXX : A multicenter and prospective study.

answer: @entity0


abstract: BACKGROUND: The prevalence of major risk factors associated to @entity3 has changed over time. Today, the frequency of @entity4 , @entity2 and @entity1 has increased, while smoking has decreased. The birth cohort effect for @entity3 in subjects as an approximation of the true prevalence over time has not been studied in Latin-America. OBJECTIVE: To determine the trends in the prevalence of major risk factors for @entity3 by birth cohort effect in a high risk population. METHODS: We estimate the prevalence of @entity1 , smoking, @entity2 and @entity4 from a prospective institutional registry (DREST registry) of @entity0 who underwent percutaneous coronary intervention for acute coronary event. Birth cohort effect was defined as a statistical, epidemiological and sociological methodology to identify the influence of the environment in the lifetime from birth by each decade. Univariate and multivariate analyses were performed adjusted by gender. RESULTS: Out of 3,056 subjects who were enrolled, 72% were male, with a median age of 61 years (interquartile range=53-69). @entity2 prevalence was 62.3%, for @entity1 it was 48.8%, for smoking it was 18.8% and for @entity4 it was 48.8%. We observed an increase in prevalence for @entity1 and @entity4 in each cohort according to birth decade, while there was a reduction in prevalence for @entity2 in the same decades. CONCLUSIONS: The prevalence of major cardiovascular risk factors has changed in time and the presence of time at birth effect is evident, possibly influenced by the environment's social conditions in each decade of life.

title: [Birth cohort effect on prevalence of cardiovascular risk factors in XXXX . Experience in a Latin-american country.]

answer: @entity3